
Cellectar Biosciences, Inc.
96
Recent developments highlight positive clinical data for iopofosine I 131 in Waldenström Macroglobulinemia, ongoing regulatory engagement, and strengthened financial position through financing activities.
- Cellectar reported positive data for iopofosine I 131 in Waldenström Macroglobulinemia, including an 8-year complete response, supporting its clinical development program [N1].
- The company held its Q2 2026 earnings call discussing progress in clinical trials and regulatory strategy [N2].
- Cellectar reported Q2 2026 financial results, highlighting strengthened cash positions supporting its oncology pipeline [N3].
- Positive Phase 2 CLOVER data for iopofosine I 131 in Waldenström Macroglobulinemia was reported, reinforcing clinical progress [N4].
- Q1 2026 earnings transcript detailed ongoing development and financial status [N5].
- The company completed a $140 million financing in May 2026 to support clinical and regulatory activities [N7].
- Cellectar’s regulatory strategy includes planned NDA submission to FDA and ongoing EMA discussions for conditional marketing approval.
- The company’s cash and liquidity ratios as of September 30, 2026, indicate a current ratio of 4.44 and cash ratio of 4.24, reflecting strong near-term liquidity [S2].
Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company developing targeted cancer therapies, primarily focusing on iopofosine I 131. The company is advancing regulatory submissions for accelerated approval in the United States and conditional marketing approval in Europe for treatment of Waldenström Macroglobulinemia patients refractory to prior therapies. Cellectar has reported positive clinical trial results from its Phase 2 CLOVER program and has initiated a Phase 3 confirmatory trial. The company’s financial position as of Q3 2026 shows liquidity sufficient for near-term operations but requires additional funding to complete its regulatory strategy. Leadership includes experienced executives and directors with backgrounds in oncology, finance, and biotechnology.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing iopofosine I 131 for treatment of Waldenström Macroglobulinemia and other cancers. The company has reported positive clinical trial data, including Phase 2 CLOVER results and an 8-year complete response. It is pursuing regulatory approvals with the FDA and EMA and has initiated a Phase 3 confirmatory trial. As of September 30, 2026, Cellectar had $24.6 million in cash and cash equivalents and a current ratio of 4.44, but reported a net loss of $7.97 million for the quarter. The company’s regulatory strategy and financing plans carry execution and dilution risks. Recent news highlights include positive clinical data and financing activities supporting the oncology pipeline.
Positive clinical trial data, including an 83.6% overall response rate in Phase 2 and an 8-year complete response, support the potential of iopofosine I 131 as a novel treatment for Waldenström Macroglobulinemia. The company’s recent $140 million financing strengthens its cash position to advance regulatory filings and Phase 3 trials. Engagement with FDA and EMA regulatory authorities and receipt of breakthrough therapy designation indicate progress in the approval pathway. Experienced leadership and strategic partnerships for isotope supply underpin operational capabilities.
Regulatory approval of iopofosine I 131 is uncertain, with FDA and EMA retaining discretion to reject filings or require additional studies. The company’s cash position, while improved, is insufficient to complete all planned trials and regulatory activities without further financing, which may not be available or may cause dilution. Failure to achieve regulatory milestones or secure funding could materially impact business operations. Competition in oncology and potential clinical trial setbacks pose additional risks.
Cellectar’s moat is based on its proprietary phospholipid drug conjugate technology platform and its lead product candidate iopofosine I 131, which has demonstrated promising clinical efficacy in treating Waldenström Macroglobulinemia and other cancers. The company’s clinical data, regulatory progress, and partnerships for isotope supply contribute to its competitive positioning. However, as a clinical-stage biopharmaceutical company, it faces typical industry risks including regulatory approval uncertainty, capital requirements, and competition from other oncology therapies.
• Regulatory Approval Risk: FDA, EMA, and other regulatory authorities have substantial discretion and may refuse to approve iopofosine I 131 based on trial design, data sufficiency, safety, or efficacy concerns. Additional studies may be required.
• Financing Risk: The company’s existing cash and proceeds from recent financing are insufficient to complete Phase 3 trials and regulatory submissions. Additional funding may be needed, which could dilute shareholders or may not be available on acceptable terms.
• Clinical Development Risk: Clinical trials may not meet endpoints or demonstrate sufficient safety and efficacy, impacting regulatory approval and commercial viability.
• Market and Dilution Risk: Milestone-based warrants could dilute existing shareholders if exercised. Market acceptance and competitive pressures in oncology could affect future prospects.
Business trends: Advancement of iopofosine I 131 clinical trials with positive Phase 2 data and initiation of Phase 3 confirmatory study; ongoing regulatory engagement with FDA and EMA.
Execution milestones: Completion of Phase 3 trial enrollment and data collection; submission and review of NDA to FDA; progress in EMA conditional marketing approval process; successful financing to support development.
Key risks: Regulatory authorities may not approve iopofosine I 131 or may require additional studies; need for additional funding beyond current cash and financing; potential dilution from warrant exercises; clinical trial and market acceptance uncertainties.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- Cellectar Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments, notably iopofosine I 131.
- The company is developing iopofosine I 131 for treatment of Waldenström Macroglobulinemia (WM) patients who have received two prior lines of therapy including a BTKi.
- Cellectar plans to submit a New Drug Application (NDA) to the FDA for accelerated approval of iopofosine I 131 and is engaged in dialogue with the European Medicines Agency (EMA) regarding conditional marketing approval (CMA).
- The company has reported positive Phase 2 CLOVER clinical trial data for iopofosine I 131 in WM, including an 83.6% overall response rate and 8-year complete response data.
- Cellectar has initiated activities related to a Phase 3 confirmatory trial for iopofosine I 131.
- The company completed a $140 million financing in May 2026 to support its oncology pipeline and regulatory strategy.
- As of September 30, 2026, Cellectar had $24.6 million in cash and cash equivalents and a current ratio of 4.44, indicating strong liquidity.
- The company reported a net loss of approximately $7.97 million and basic and diluted EPS of -$0.46 for the quarter ended September 30, 2026.
- Cellectar's regulatory strategy carries risks including potential FDA or EMA rejection or requests for additional studies, and the need for additional funding to complete clinical trials and regulatory submissions.
- The company issued milestone-based warrants in May 2026 that could provide up to $105 million if exercised, but exercise is contingent on achieving milestones and stock price/volume thresholds, with potential dilution risk to existing shareholders.
- The company’s leadership includes experienced executives and directors with backgrounds in biotechnology, finance, and oncology.
- Cellectar has publicly disclosed its financials and regulatory risks in SEC filings including an amended 10-K and a recent 10-Q.
- The company’s stock underwent a one-for-thirty reverse split effective June 24, 2025.
- Cellectar has partnerships for long-term supply of isotopes iodine-125 and actinium-225 to support its cancer treatment development.
Generated 2026-11-10
- N2
- N5
- N8
- S1 | 2026-04-30 | 10-K/A
- S2 | 2026-11-10 | 10-Q
- N1 | 2026-09-29 | www.nasdaq.com | Cellectar's Iopofosine I 131 Shows Positive Data In Waldenström Macroglobulinemia | https://www.nasdaq.com/articles/cellectars-iopofosine-i-131-shows-positive-data-waldenstrom-macroglobulinemia
- N2 | 2026-08-20 | www.nasdaq.com | Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript | https://www.nasdaq.com/articles/cellectar-biosciences-clrb-q2-2026-earnings-call-transcript
- N3 | 2026-08-13 | www.nasdaq.com | Cellectar Reports Q2 2026 Results, Strengthened Cash Positions Supports Oncology Pipeline | https://www.nasdaq.com/articles/cellectar-reports-q2-2026-results-strengthened-cash-positions-supports-oncology-pipeline
- N4 | 2026-06-02 | www.nasdaq.com | Cellectra Reports Positive Phase 2 CLOVER Data For Iopofosine I 131 In Waldenstrom Macroglobulinemia | https://www.nasdaq.com/articles/cellectra-reports-positive-phase-2-clover-data-iopofosine-i-131-waldenstrom
- N5 | 2026-05-14 | www.nasdaq.com | Cellectar (CLRB) Q1 2026 Earnings Transcript | https://www.nasdaq.com/articles/cellectar-clrb-q1-2026-earnings-transcript
- N6 | 2026-05-08 | www.nasdaq.com | Weekly Buzz:FDA Clears Tab-cel Path, Arvinas Wins PROTAC Nod, Novartis Cuts Jobs, Roche Buys PathAI | https://www.nasdaq.com/articles/weekly-buzz-fda-clears-tab-cel-path-arvinas-wins-protac-nod-novartis-cuts-jobs-roche-buys
- N7 | 2026-05-05 | www.nasdaq.com | Cellectar Share Surge On $140M Financing And Strong 12-Month CLOVER-WaM Phase 2b Data | https://www.nasdaq.com/articles/cellectar-share-surge-140m-financing-and-strong-12-month-clover-wam-phase-2b-data
- N8 | 2026-03-04 | www.nasdaq.com | Cellectar (CLRB) Q4 2025 Earnings Call Transcript | https://www.nasdaq.com/articles/cellectar-clrb-q4-2025-earnings-call-transcript
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


